Table 1. Correlation between LncRNA MIR22HG expression and clinicopathologic features.
| Variables | LncRNA MIR22HG expression | |||
|---|---|---|---|---|
| Low(n=53) | High(n=74) | P | ||
| Sex | female | 20 | 22 | 0.344 |
| male | 33 | 52 | ||
| Age | median | 53 | 51 | 0.251 |
| range | 20-70 | 32-71 | ||
| AFP level (μg/L) | <400 | 25 | 32 | 0.661 |
| >400 | 28 | 42 | ||
| HBsAg | positive | 42 | 59 | 0.947 |
| negative | 11 | 15 | ||
| HBeAg | positive | 36 | 47 | 0.606 |
| negative | 17 | 27 | ||
| Liver cirrhosis | yes | 26 | 43 | 0.313 |
| no | 27 | 31 | ||
|
Edmondson-Steiner grade |
I-II | 19 | 32 | 0.475 |
| III- IV | 34 | 42 | ||
| Diameter (cm) | ≤5 | 28 | 36 | 0.642 |
| >5 | 25 | 38 | ||
| Encapsulation | complete | 15 | 39 | 0.006 |
| no | 38 | 35 | ||
| MVI | yes | 34 | 31 | 0.013 |
| no | 19 | 43 | ||
| Tumor number | single | 41 | 56 | 0.826 |
| multiple | 12 | 18 | ||
| TBL (umol/l) | median | 13.5 | 15.7 | 0.671 |
| range | 4.26-68.32 | 4.27-72.41 | ||
| Alb (g/dl) | median | 39.3 | 38.6 | 0.173 |
| range | 24.5-51.4 | 23.6-53.8 | ||
| ALT (U/L) | median | 63.2 | 67.3 | 0.801 |
| range | 12.4-238.3 | 7.8-276.2 | ||
| PLT (*109/L) | median | 127 | 125 | 0.703 |
| range | 28-375 | 21-382 | ||
| INR | median | 1.05 | 1.04 | 0.285 |
| range | 0.87-1.26 | 0.89-1.23 | ||
| CR | median | 72 | 63 | 0.341 |
| range | 40-147 | 38-172 | ||
| TNM stage: | I | 6 | 19 | 0.020 |
| II | 21 | 35 | ||
| III | 26 | 20 | ||
AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; HBeAg, Hepatitis E antigen; MVI, microvascular invasion; TBIL, total bilirubin; ALB, albumin; ALT, alanine; PLT, platelet count; INR, international normalized ratio; CR, creatinine.